Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Tae-Hwe Heo 1,2 , Joseph Wahler 2 and Nanjoo Suh 2,3 1 NP512, Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Seoul, Republic of Korea 2 Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA 3 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA Correspondence to: Tae-Hwe Heo, email: // Nanjoo Suh, email: // Keywords : breast cancer, interleukin-6, gp130 Received : October 05, 2015 Accepted : January 23, 2016 Published : January 31, 2016 Abstract Interleukin-6 (IL-6) is a pleiotropic cytokine with known multiple functions in immune regulation, inflammation, and oncogenesis. Binding of IL-6 to the IL-6 receptor (IL-6R) induces homodimerization and recruitment of glycoprotein 130 (gp130), which leads to activation of downstream signaling. Emerging evidence suggests that high levels of IL-6 are correlated with poor prognosis in breast cancer patients. IL-6 appears to play a critical role in the growth and metastasis of breast cancer cells, renewal of breast cancer stem cells (BCSCs), and drug resistance of BCSCs, making anti–IL-6/IL-6R/gp130 therapies promising options for the treatment and prevention of breast cancers. However, preclinical and clinical studies of the applications of anti–IL-6/IL-6R/gp130 therapy in breast cancers are limited. In this review, we summarize the structures, preclinical and clinical studies, mechanisms of action of chemical and biological blockers that directly bind to IL-6, IL-6R, or gp130, and the potential clinical applications of these pharmacological agents as breast cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Triple-negative breast cancer: epidemiological considerations and recommendations
Boyle, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds187 · Cited by 593
Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308 · cited 1×
“In contrast, sIL-6R, which is generated by alternative splicing and/or proteolysis, can bind to IL-6 and elicit trans-signaling in all cells due to ubiquitous expression of membrane gp130 [20-22].”
BackgroundHartman, Z. C., Yang, X.-Y., Glass, O., Lei, G., Osada, T., Dave, S. S., Morse, M. A., Clay, T. M., & Lyerly, H. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0308 · Cited by 137 · cited 2×
“Further evidence revealed that the growth of HER2positive breast cancer in vivo was dependent on the HER2/ IL-6/STAT3 signaling pathway [36].”
Background
Cited by
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Weng, Y.-S., Tseng, H.-Y., Chen, Y.-A., Shen, P.-C., Al Haq, A. T., Chen, L.-M., Tung, Y.-C., & Hsu, H.-L. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0988-0 · Cited by 444
Kitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H., Takahashi, N., & Taketomi, A. (2017) · Cancer Science · doi:10.1111/cas.13332 · Cited by 278
“42) Previous papers revealed that IL-6 promotes growth and epithelial – mesenchymal transition of CD133 + cells of non-small cell lung cancer, (48) tumorigenicity of oral cancer stem cells, (49) cell adhesion, cancer stem-like and metastatic spread of prostate tumors, (50) the growth and metastasis of breast cancer ce…”
BackgroundTumor-related interleukins: old validated targets for new anti-cancer drug development
Setrerrahmane, S., & Xu, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0721-9 · Cited by 237
“Finally, the mAb sarilumab showed a good effect both as a single agent or in combination with aflibercept, an inhibitor of VEGF [141].”
InfluentialThe pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells
Ryan, D., Paul, B. T., Koziol, J., & ElShamy, W. M. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1131-2 · Cited by 25
A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer
Liu, X., Chen, B., Chen, J., & Sun, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08066-2 · Cited by 24
Metadata
- Authors
- Heo, T.-H., Wahler, J., & Suh, N.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-01-31
- Volume
- 7
- Issue
- 13
- Pages
- 15460-15473
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2291386925
- Cited by
- 122
- References
- 5
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.